Vincent Brichard

9.3k total citations · 2 hit papers
73 papers, 5.9k citations indexed

About

Vincent Brichard is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Vincent Brichard has authored 73 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Immunology, 40 papers in Molecular Biology and 34 papers in Oncology. Recurrent topics in Vincent Brichard's work include Immunotherapy and Immune Responses (64 papers), vaccines and immunoinformatics approaches (32 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Vincent Brichard is often cited by papers focused on Immunotherapy and Immune Responses (64 papers), vaccines and immunoinformatics approaches (32 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Vincent Brichard collaborates with scholars based in Belgium, France and United States. Vincent Brichard's co-authors include Thierry Boon, Aline Van Pel, Thomas Wölfel, Pierre G. Coulie, Etienne De Plaen, Bernard Lethé, Jamila Louahed, Catherine Wölfel, Jean‐Christophe Renauld and Christophe Lurquin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Vincent Brichard

70 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 785 citations Vincent Brichard, Aline Van Pel et al. The Journal of Experimental Medicine profile →
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1994 767 citations Pierre G. Coulie, Vincent Brichard et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent Brichard Belgium	37	4.8k	2.6k	2.4k	504	333	73	5.9k
Matteo Bellone Italy	36	2.6k 0.5×	1.6k 0.6×	1.8k 0.7×	366 0.7×	291 0.9×	110	4.6k
Benoı̂t Van den Eynde Belgium	26	4.6k 1.0×	2.1k 0.8×	2.8k 1.2×	494 1.0×	458 1.4×	51	5.9k
Astar Winoto United States	45	4.4k 0.9×	1.7k 0.6×	4.7k 2.0×	589 1.2×	721 2.2×	83	8.3k
Ada M. Kruisbeek Netherlands	49	5.4k 1.1×	1.8k 0.7×	2.0k 0.8×	906 1.8×	684 2.1×	122	7.3k
Lea Eisenbach Israel	33	2.5k 0.5×	1.5k 0.6×	2.1k 0.9×	427 0.8×	570 1.7×	123	4.4k
B. J. Fowlkes United States	45	5.7k 1.2×	1.3k 0.5×	1.8k 0.7×	1.2k 2.3×	474 1.4×	77	7.5k
Richard A. Maki United States	40	3.4k 0.7×	1.0k 0.4×	3.3k 1.4×	1.0k 2.0×	570 1.7×	81	6.8k
Barbara A. Malynn United States	34	3.3k 0.7×	815 0.3×	2.7k 1.1×	312 0.6×	489 1.5×	48	5.6k
Etienne De Plaen Belgium	40	8.7k 1.8×	4.0k 1.6×	5.6k 2.3×	1.0k 2.1×	930 2.8×	74	11.1k
William G. Kerr United States	34	2.4k 0.5×	1.2k 0.5×	2.3k 1.0×	200 0.4×	499 1.5×	109	5.2k

Countries citing papers authored by Vincent Brichard

Since Specialization

Citations

This map shows the geographic impact of Vincent Brichard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Brichard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Brichard more than expected).

Fields of papers citing papers by Vincent Brichard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Brichard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Brichard. The network helps show where Vincent Brichard may publish in the future.

Co-authorship network of co-authors of Vincent Brichard

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Brichard. A scholar is included among the top collaborators of Vincent Brichard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Brichard. Vincent Brichard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dizier, Benjamin, Andrea Callegaro, Muriel Debois, et al.. (2019). A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(7). 1725–1735. 13 indexed citations

Curigliano, Giuseppe, Vincenzo Bagnardi, Jamila Louahed, et al.. (2019). Expression of tumor-associated antigens in breast cancer subtypes. The Breast. 49. 202–209. 26 indexed citations

Curigliano, Giuseppe, Gilles Romieu, Mario Campone, et al.. (2016). A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 156(2). 301–310. 41 indexed citations

Pujol, Jean-Louis, Johan Vansteenkiste, Tommaso Martino De Pas, et al.. (2015). Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(10). 1458–1467. 51 indexed citations

Louahed, Jamila, Brigitte Dréno, Swann Gaulis, et al.. (2008). Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment. Annals of Oncology. 19. 27. 8 indexed citations

Jassem, J, Johan Vansteenkiste, M. Zieliński, et al.. (2008). GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology. 19. 61–61. 2 indexed citations

Vansteenkiste, Johan, A. Linder, Emilio Esteban, et al.. (2007). B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. Journal of Thoracic Oncology. 2(8). S334–S335. 4 indexed citations

Brichard, Vincent & Diane Lejeune. (2007). GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine. 25. B61–B71. 120 indexed citations

Brichard, Vincent. (2005). Development of cancer vaccines with the MAGE-3 protein. 5. 16. 3 indexed citations

10.

Curigliano, Giuseppe, Gianluca Spitaleri, Elisabetta Pietri, et al.. (2005). Breast cancer vaccines: a clinical reality or fairy tale?. Annals of Oncology. 17(5). 750–762. 78 indexed citations

11.

Brichard, Vincent & Catherine Gérard. (2003). Melanoma vaccines: achievements and perspectives.. PubMed. 13(2). 144–54; quiz 189. 2 indexed citations

12.

Morel, Sandra, et al.. (1999). A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. International Journal of Cancer. 83(6). 755–759. 25 indexed citations

13.

Balligand, Jean‐Luc, et al.. (1998). Hypoleptinemia in patients with anorexia nervosa: loss of circadian rhythm and unresponsiveness to short-term refeeding. European Journal of Endocrinology. 138(4). 415–420. 46 indexed citations

14.

Skipper, Jonathan, Ronald C. Hendrickson, Pamela H. Gulden, et al.. (1996). An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.. The Journal of Experimental Medicine. 183(2). 527–534. 346 indexed citations

15.

Levraud, Jean‐Pierre, Christophe Pannetier, Pierre Langlade‐Demoyen, Vincent Brichard, & Philippe Kourilsky. (1996). Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.. The Journal of Experimental Medicine. 183(2). 439–449. 48 indexed citations

16.

Guilloux, Yannick, Sophie Lucas, Vincent Brichard, et al.. (1996). A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.. The Journal of Experimental Medicine. 183(3). 1173–1183. 179 indexed citations

17.

Bruggen, Pierre van der, Benoı̂t Van den Eynde, Pierre G. Coulie, et al.. (1995). Genes encoding human tumor-antigens recognized by cytolytic T-lymphocytes. Journal of Cellular Biochemistry. 6–6. 2 indexed citations

18.

Wölfel, Thomas, Aline Van Pel, Vincent Brichard, et al.. (1994). Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes. European Journal of Immunology. 24(3). 759–764. 345 indexed citations

19.

Coulie, Pierre G., P. Weynants, Frédéric Lehmann, et al.. (1993). Genes Coding for Tumor Antigens Recognized by Human Cytolytic T Lymphocytes. Journal of Immunotherapy. 14(2). 104–109. 42 indexed citations

20.

Wölfel, Thomas, M. Hauer, Vincent Brichard, et al.. (1993). Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL). International Journal of Cancer. 55(2). 237–244. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact